Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)

This study tests a combination of two drugs — SHR-A2102 (an antibody-drug conjugate) and adebrelimab (an immunotherapy drug) — given before surgery for people with muscle-invasive bladder cancer. The goal is to shrink the cancer before removing the bladder, and potentially improve survival. **You may be eligible if:** - You are 18 or older - You have been diagnosed with muscle-invasive bladder cancer that has not spread to distant organs - Your cancer has been confirmed by pathology and imaging - You are in good general health (ECOG score 0 or 1) - Your expected survival is at least 2 years - You have not received prior treatment for this cancer **You may NOT be eligible if:** - Your bladder cancer has spread to other organs (metastatic) - You have received previous chemotherapy, radiation, or immunotherapy for bladder cancer - You are pregnant - You have serious kidney, liver, or heart problems Talk to your doctor to see if this trial is right for you.